Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGI-0301 Plus Nivolumab in Advanced HCC or RCC
NCT07494435Phase 2Not yet recruiting
- Sponsor
- Haichang Biotech
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Modified DNA Oligonucleotides, Lipid-based Nanoparticles, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of WGI-0301 in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), sponsored by Haichang Biotech. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
WGI-0301
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07494435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07494435.